-
Document de presse | 2015.01.26
Patronage: the Institut Pasteur and the Total Foundation renew their common commitment against infectious diseases
For 10 years, Total and its corporate foundation working alongside the Institut Pasteur and its International Network in the fight against infectious diseases. A new sponsorship agreement, of EUR 6 million for three years, was signed on 26 January 2015. It will provide funding, for public health and research projects in resource limited countries in order to better understand the therapeutic and...
-
News | 2021.05.31
Diphtheria outbreak in Yemen: an epidemiology study
Diphtheria is a severe infection caused in humans by toxigenic strains of Corynebacterium diphtheriae bacteria. If left untreated, it leads to death in 5 to 25% of cases. It generally affects the upper respiratory tracts, causing pseudomembrane formation and sometimes leading to suffocation. The infection can be complicated by systemic symptoms caused by the diphtheria toxin. Scientists from the...
-
Document de presse | 2012.02.09
Newly characterized dengue virus antibody shows promise
Research teams from the Institut Pasteur, the CNRS, and Inserm have recently characterized the structure and mechanism of action of an antibody that successfully neutralizes all four strains of the dengue virus in mice models. Their groundbreaking work represents major progress for research efforts that hope to develop an effective vaccine to combat this disease. This study was published February...
-
Fiche maladie | 2024.03.12
Mpox (formerly monkeypox)
Mpox is a virus that was initially present in animals, especially rodents in Africa, and now circulates among humans – it is referred to as an emerging zoonotic disease. The disease caused by this virus is also known as mpox (formerly monkeypox), and presents as a mild form of smallpox, with less severe symptoms and a lower case-fatality rate (the number of deaths as a proportion of the number of...
-
Article | 2024.02.01
International programs
To meet current global health challenges, the Institut Pasteur is developing and coordinating major international projects, run mainly in conjunction with members of the Institut Pasteur International Network. As well as furthering knowledge, these programs help to increase local skills, build up equipment, and assist health authorities in drawing up recommendations to improve the care of...
-
Document de presse | 2021.03.26
COVID-19: analysis of the sensitivity of the UK (B.1.1.7) and South African (B.1.351) variants to SARS-CoV-2 neutralizing antibodies
The B.1.1.7 and B.1.351 variants of SARS-CoV-2 were first detected in the UK and South Africa respectively, and have since spread to many other countries. Scientists from the Institut Pasteur joined forces with Orléans Regional Hospital, Tours University Hospital, Créteil Intercommunal Hospital, Strasbourg University Hospital and Georges Pompidou European Hospital to study the sensitivity of...
-
Document de presse | 2025.06.04
Vigilance and targeted public health measures are essential in the face of the diphtheria epidemic that has affected vulnerable populations in Western Europe since 2022
A study published in the New England Journal of Medicine (NEJM) reveals that the largest diphtheria epidemic in Western Europe for 70 years, which broke out in 2022 among migrants and in 2023 spread to other vulnerable populations in several European countries, is the result of contaminations occurring during migratory travel or in destination European countries, and not in the countries of...
-
News | 2017.05.09
The Zika virus modifies the morphology of the cells and makes them implode
Researchers at the Institut Pasteur (Paris) and Inserm* have successfully filmed the infection of human cells by the Zika virus, using video microscopy. Significant morphological changes to the cell were observed, whereas the cytopathic effects of the Zika virus were hitherto poorly characterized. This allows the virus to multiply before the cell implodes.*This work was supported by grants from...
-
Document de presse | 2021.05.28
COVID-19: analysis of the sensitivity of the Delta variant to monoclonal antibodies and sera from convalescent and vaccinated individuals
The Delta variant was detected for the first time in India in October 2020 and has since spread throughout the world. It is now dominant in many countries and regions (India, the UK, Portugal, Russia, etc.) and is predicted to be the most prevalent variant in Europe within weeks or months. Epidemiological studies have shown that the Delta variant is more transmissible than other variants....
-
Document de presse | 2025.02.12
Mpox: a better understanding of tecovirimat resistance
A virus originally found in animals, mpox – which causes the disease of the same name – is now circulating in humans. Since 2022, it has been the cause of major epidemics spreading outside endemic areas in Central and West Africa. Two hundred and fifteen cases of mpox infection were reported to Santé publique France in 2024. Tecovirimat is the drug most commonly used to treat patients infected...